Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Deferred Revenue (2021 - 2025)

Senti Biosciences has reported Current Deferred Revenue over the past 5 years, most recently at $304000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $304000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $304000.0 (changed N/A YoY), and the annual figure for FY2025 was $304000.0, changed.
  • Current Deferred Revenue for Q4 2025 was $304000.0 at Senti Biosciences, down from $360000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SNTI hit a ceiling of $1.7 million in Q4 2021 and a floor of $99000.0 in Q3 2022.
  • Median Current Deferred Revenue over the past 5 years was $718500.0 (2024), compared with a mean of $676428.6.
  • Peak annual rise in Current Deferred Revenue hit 957.58% in 2023, while the deepest fall reached 80.31% in 2023.
  • Senti Biosciences' Current Deferred Revenue stood at $1.7 million in 2021, then crashed by 51.75% to $799000.0 in 2022, then rose by 23.78% to $989000.0 in 2023, then plummeted by 35.39% to $639000.0 in 2024, then plummeted by 52.43% to $304000.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $304000.0 (Q4 2025), $360000.0 (Q2 2025), and $513000.0 (Q1 2025) per Business Quant data.